Redeye provides an update following Strax Q3-results wich saw weak topline, higher costs and no news regarding divestments of their business units. In the short term, the outlook remains uncertain with the large debt in focus. On the other hand,
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
© Modular Finance, source